RSV Antiviral Zelicapavir Enters Late-stage Clinical Trials
Enanta Pharma advanced zelicapavir into a registrational Phase 2b/3 clinical trial for adults at high risk of severe RSV outcomes.
Tag: antiviral
All
Latest
RSV Antiviral Zelicapavir Enters Late-stage Clinical Trials
Enanta Pharma advanced zelicapavir into a registrational Phase 2b/3 clinical trial for adults at high risk of severe RSV outcomes.
Read More
FDA Approves Generic Xofluza
The FDA approved the first generic of Xofluza (baloxavir marboxil) tablets, the first single-dose treatment for acute uncomplicated influenza and prophylaxis in patients 5 years of age and older.
Read More
Certain Flu Drugs May Reduce Cognitive Decline
Researchers found that sialidase inhibitors—a class of flu drugs including oseltamivir (Tamiflu)—protected against degradation of protective sugar molecules tied to cognitive decline and premature aging in people living with HIV.
Read More
Phase II Trial for Antiviral Nasal Spray Advances to Next Stage
The once-weekly INNA-051 treatment from ENA Respiratory aims to prime the immune system to protect high-risk patients from influenza, RSV, and other respiratory viruses.
Read More
Metformin, UDCA Fail to Improve Long COVID Recovery
A two-week course of metformin or ursodeoxycholic acid (UDCA) did not meaningfully improve recovery from long COVID symptoms.
Read More
ACP Issues Final Guidance on COVID-19 Antivirals
The American College of Physicians (ACP) issued its final update on antiviral treatment for COVID‑19 in outpatient settings.
Read More
Paxlovid for Hemodialysis Patients with COVID-19
Researchers investigated the safety and efficacy of Paxlovid (nirmatrelvir/ritonavir) for hemodialysis-dependent patients with COVID-19.
Read More
Flawed Data in COVID Antiviral Development
New research discovered that data used in the development of SARS-Cov-2 antivirals contained major errors.
Read More
FDA Approves Enflonsia to Prevent RSV-related LRTIs in Neonates
The FDA approved Enflonsia, a long-acting monoclonal antibody designed to protect neonates and infants from RSV-related lower respiratory tract disease.
Read More
Novel COVID Antiviral May Overcome Paxlovid Limitations
In laboratory testing, new drug candidate Jun13296 remained effective against Paxlovid-resistant strains of the coronavirus SARS-CoV-2.
Read More
Current Antivirals Less Effective Against Severe Bird Flu
Two FDA–approved flu antivirals did not successfully treat severe H5N1 infections, and route of infection (eye, nose or mouth) significantly impacted effectiveness.
Read More
Researchers Question Paxlovid’s Impact on COVID-19 Outcomes
Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to UCLA-led research.
Read More
New Approach for Antiviral Development
A new antiviral modeling approach combines various experimental techniques to create a comprehensive picture of a virus’ dynamic behavior.
Read More
Walgreens Launches 2024-2025 Flu Index to Track Weekly Flu Activity
The online tool provides weekly updates on flu activity across states and cities, highlighting regions with the highest increases and historical trends.
Read More
Pneumonia: Etiology, Care and Prevention
Pneumonia is a potentially life-threatening infection of the lungs that inflames alveoli and spurs the overproduction of purulent material. Typically afflicting neonates and seniors, the COVID pandemic has revealed the importance of proper pneumonia care for all patients.
Read More
Oral COVID-19 Drug Candidate Ratutrelvir Shows Promise in Early Trial
Topline results demonstrated that the drug was well-tolerated over a 10-day period and achieved consistent plasma levels without the need for ritonavir co-administration.
Read More
NIH Panel Provides Final COVID-19 Treatment Recommendations
Future updates to COVID-19 treatment recommendations will transition to professional medical societies.
Read More
Texas Dairy Worker with Bird Flu Had Pinkeye, No Respiratory Symptoms
A new case report sheds light on the first documented transmission of bird flu from cow to human.
Read More
Investigational Drug Prevents Flu-induced Lung Injury
UH15-38 shows potential in preventing lung injury and reducing inflammation in severe influenza when administered even five days after infection.
Read More
Merck’s COVID Drug May be Causing the Virus to Mutate
Researchers identified unusual COVID-19 mutation patterns that were strongly associated with molnupiravir use and coincided with the drug’s introduction.
Read More
Pharmacological Treatment of Respiratory Disorders
In this 2023 update of RT’s pharmacological treatment of respiratory disorders, the most commonly administered classes of pulmonary medications are reviewed.
Read More
FDA Approves Paxlovid for High-Risk COVID-19 Patients
Pfizer’s Paxlovid is the fourth drug—and first oral antiviral pill—approved by the FDA to treat COVID-19 in adults.
Read More
Antivirals Could Combat Emerging Infectious Diseases
Researchers identified potential broad-spectrum antiviral agents that can target multiple families of RNA viruses that pose a significant threat for future pandemics.
Read More
FDA Fast Tracks Investigational COVID-19 Oral Antiviral
The oral, direct-acting antiviral drug candidate is being evaluated in the global phase 3 SUNRISE-3 registrational trial for the treatment of COVID-19 in outpatients at high risk for disease progression regardless of vaccination status.
Read More